120 related articles for article (PubMed ID: 30952743)
1. Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Miyakita H; Chan LF; Kamei Y; Kajiwara H; Nagase H
Anticancer Res; 2019 Apr; 39(4):1997-2005. PubMed ID: 30952743
[TBL] [Abstract][Full Text] [Related]
2. Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Nagase H; Uchida J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):285-91. PubMed ID: 22752215
[TBL] [Abstract][Full Text] [Related]
3. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
4. Reduction in γ-glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Kamijo A; Nagase H; Uchida J
Anticancer Res; 2013 Aug; 33(8):3431-8. PubMed ID: 23898115
[TBL] [Abstract][Full Text] [Related]
5. Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
Hsu TC; Wang CC
J Comp Eff Res; 2019 Jan; 8(2):73-79. PubMed ID: 30560687
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).
Miyake Y; Nishimura J; Kato T; Ikeda M; Tsujie M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Surg Today; 2018 Jan; 48(1):66-72. PubMed ID: 28634730
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone.
Tsunoda A; Nakao K; Tsunoda Y; Watanabe M; Matsui N
Int J Clin Oncol; 2010 Apr; 15(2):153-60. PubMed ID: 20191299
[TBL] [Abstract][Full Text] [Related]
10. Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients.
Meguro M; Furuhata T; Okita K; Nishidate T; Ishiyama G; Iwayama Y; Kimura Y; Mizuguchi T; Hirata K
Int J Clin Oncol; 2009 Oct; 14(5):402-7. PubMed ID: 19856047
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of uracil/tegafur (UFT) plus oral Leucovorin (LV) therapy for colorectal cancer in elderly patients].
Mizushima T; Mizuno H; Ito T; Hoki M; Souma Y; Iwamoto T; Ozawa H; Kanou T; Nakamori Y; Iwase K
Gan To Kagaku Ryoho; 2006 Jul; 33(7):941-4. PubMed ID: 16835484
[TBL] [Abstract][Full Text] [Related]
14. Combined Low Densities of FoxP3
Cavalleri T; Bianchi P; Basso G; Celesti G; Grizzi F; Bossi P; Greco L; Pitrone C; Valtorta E; Mauri G; Truini M; Dall'Olio FG; Brandi G; Sartore-Bianchi A; Ricciardiello L; Torri V; Rimassa L; Siena S; Mantovani A; Malesci A; Laghi L;
Cancer Immunol Res; 2019 May; 7(5):751-758. PubMed ID: 30804005
[TBL] [Abstract][Full Text] [Related]
15. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Saiura A; Yamamoto J; Hasegawa K; Oba M; Takayama T; Miyagawa S; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Makuuchi M; Kokudo N
Drug Discov Ther; 2014 Feb; 8(1):48-56. PubMed ID: 24647158
[TBL] [Abstract][Full Text] [Related]
16. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
17. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of UFT plus leucovorin in colorectal cancer.
Pazdur R
Oncology; 1997; 54 Suppl 1():19-23. PubMed ID: 8978580
[TBL] [Abstract][Full Text] [Related]
19. [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer].
Maruyama T; Yasuda K; Sako A; Ueda K; Okumura M
Gan To Kagaku Ryoho; 2016 Jan; 43(1):69-72. PubMed ID: 26809528
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial).
Kosugi C; Koda K; Takiguchi N; Takaishi S; Miyauchi H; Hirayama N; Nomura Y; Kondo E; Kawasaki Y; Ozawa Y; Matsubara H
Int J Colorectal Dis; 2021 Aug; 36(8):1739-1749. PubMed ID: 33715077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
